Clinical Trial Update: Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and efficacy of converting maintenance tacrolimus to cyclosporine micro-emulsion in kidney and liver transplant recipients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• New-onset Diabetes After Transplantation

Drugs mentioned

• Cyclosporine micro-emulsion (Cyclosporine)
• Tacrolimus (Prograf) (tacrolimus)

Snippet

Sponsor: Novartis | Conditions: Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients | Phase 4 | Status: TERMINATED